Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| enzymes | 5321 | 941577-06-6 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ASPARLAS is thought to be based on selective killing of leukemic cells due to depletion of plasma L-asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize L-asparagine, and therefore depend on an exogenous source of L-asparagine for survival.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 20, 2018 | FDA | SERVIER PHARMA LLC |
None
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypertriglyceridaemia | 87.06 | 66.28 | 19 | 482 | 16135 | 110572663 |
| Treatment delayed | 73.89 | 66.28 | 10 | 491 | 497 | 110588301 |
| Infusion related reaction | 73.18 | 66.28 | 35 | 466 | 381127 | 110207671 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01XX86 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| FDA CS | M0001815 | Asparaginase |
| FDA EPC | N0000175669 | Asparagine-specific Enzyme |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute lymphoblastic leukemia | indication | 413440007 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| T9FVH03HMZ | UNII |
| C2699709 | UMLSCUI |
| CHEBI:753666 | CHEBI |
| CHEMBL2108728 | ChEMBL_ID |
| DB14730 | DRUGBANK_ID |
| D10096 | KEGG_DRUG |
| 9250 | INN_ID |
| C000595188 | MESH_SUPPLEMENTAL_RECORD_UI |
| 783683008 | SNOMEDCT_US |
| 783687009 | SNOMEDCT_US |
| 303899 | MMSL |
| 35900 | MMSL |
| d09115 | MMSL |
| 2121416 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| asparlas | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72694-515 | INJECTION, SOLUTION | 750 U | INTRAVENOUS | BLA | 28 sections |